Show
The pharmaceutical, biotechnology and MedTech industries are under intense pressure to deliver and introduce new drugs and technology despite tightened budgets and the closure and relocation of many R&D centers. R&D tax incentives offer a solution that may assist with the funding of R&D programs to help companies remain competitive, improve access to medicine and deliver a fast turnaround of disease diagnostics for patients. Additional R&D tax deduction
R&D tax relief is available primarily for expenses associated with qualifying personnel directly involved in R&D in Switzerland. In addition, contract R&D in Switzerland is eligible as well. The level of additional R&D tax deduction varies from canton to canton but could provide up to an additional 50% deduction against the company’s taxable income at cantonal and municipal level. How does it work?
The Swiss R&D incentive schemes, focusing on additional R&D tax deductions, are designed to recognize and reward companies incurring expenditure on R&D projects. Qualifying expenditure attracts an additional R&D tax deduction if the R&D is conducted in Switzerland. The level of the additional R&D tax deduction varies (max. 50%) but could provide an additional tax deduction against the company’s taxable income on qualifying R&D expense calculated as follows:
Scientific research and science-based innovation activities across any sector may qualify. In order to qualify, R&D activity needs to meet the respective criteria (i.e. novelty, creativity, uncertainty, systematic approach and transferability and/or reproducibility) of the OECD’s Frascati Manual. What types of activities can qualify?
The definition of R&D for Swiss tax purposes is much broader than the indicative list below. We would expect that – among others – the following activities in the pharmaceutical, biotechnology and MedTech industries could qualify for R&D tax deduction:
What is the benefit?
As an example, a profit-making company in Zurich that operates R&D and has CHF 1 million qualifying R&D expenses can benefit from an additional tax deduction for R&D of CHF 500,000. This would result in an annual tax benefit of approx. CHF 72,000 per CHF 1 million of qualifying expense resulting in 7.2% cost saving for R&D. Patent box for successful R&D
In the case of successful R&D in the pharmaceutical, biotechnology and MedTech sectors, the patent box is another tax incentive for reduced taxation of profits. The reduction of patent-related profits amounts to a maximum of 90% for cantonal and municipal taxes and depends on the respective canton of domicile. The reduced taxation can be applied to profits from Swiss, European and foreign patents, supplementary protection certificates for medicinal products as well as documents on medicinal products with new active ingredients or new indicators, administration routes and dosages.
Tags:Read Online (Free) relies on page scans, which are not currently available to screen readers. To access this article, please contact JSTOR User Support . We'll provide a PDF copy for your screen reader. With a personal account, you can read up to 100 articles each month for free. Get StartedAlready have an account? Log in Monthly Plan
Yearly Plan
Log in through your institution Purchase a PDFPurchase this article for $26.00 USD. How does it work?
journal article German Politics & Society Vol. 14, No. 3 (40) (Fall 1996) , pp. 31-53 (23 pages) Published By: Berghahn Books https://www.jstor.org/stable/23736370 Read and download Log in through your school or library Alternate access options For independent researchers Read Online Read 100 articles/month free Subscribe to JPASS Unlimited reading + 10 downloads Purchase article $26.00 - Download now and later Journal Information German Politics and Society is a joint publication of the BMW Center for German and European Studies (of the Edmund A. Walsh School of Foreign Service, Georgetown University) and the German Academic Exchange Service (DAAD). These centers are represented by their directors on the journal's Editorial Committee. German Politics and Society is a peer-reviewed journal published and distributed by Berghahn Journals. It is the only American publication that explores issues in modern Germany from the combined perspectives of the social sciences, history, and cultural studies. The journal provides a forum for critical analysis and debate about politics, history, film, literature, visual arts, and popular culture in contemporary Germany. Every issue includes contributions by renowned scholars commenting on recent books about Germany. Publisher Information Berghahn Books is an award-winning independent scholarly publisher of distinguished books and journals in the humanities and social sciences, headed by a mother (books) and daughter (journals) team. Its program, which includes 35 journals to date and 100 new titles a year, is focused on History, Sociology & Anthropology, International Politics & Policy Studies, Cultural and Media Studies, Jewish Studies, and Migration & Refugee Studies. A peer-reviewed press, Berghahn is committed to the highest academic standards; its publishing program is widely recognized for the quality both of its lists and of the production of its books and journals. Rights & Usage
This item is part of a JSTOR Collection. |